

Paola Rogliani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1341783/publications.pdf>

Version: 2024-02-01

368
papers

8,814
citations

53794

45
h-index

79698

73
g-index

371
all docs

371
docs citations

371
times ranked

8914
citing authors

#	ARTICLE	IF	CITATIONS
1	Lessons from peculiar cases of anaphylaxis: why allergists should be prepared for the unexpected. European Annals of Allergy and Clinical Immunology, 2022, 54, 99.	1.0	3
2	The Future of Bronchodilators in COPD and Asthma. Archivos De Bronconeumologia, 2022, 58, 107-108.	0.8	4
3	Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies. Expert Review of Respiratory Medicine, 2022, 16, 357-365.	2.5	3
4	Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis. Drugs, 2022, 82, 1-13.	10.9	12
5	Synergy across the drugs approved for the treatment of asthma. Minerva Medica, 2022, 113, .	0.9	6
6	Beyond Dual Bronchodilation – Triple Therapy, When and Why. International Journal of COPD, 2022, Volume 17, 165-180.	2.3	9
7	Efficacy of respiratory tele-rehabilitation in COPD patients: Systematic review and meta-analysis. Monaldi Archives for Chest Disease, 2022, , .	0.6	10
8	First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario?. Microorganisms, 2022, 10, 268.	3.6	12
9	COVID-19 lockdown, personal protective equipment, hyper-hygiene and allergy. European Annals of Allergy and Clinical Immunology, 2022, , .	1.0	0
10	Use of face masks and allergic rhinitis from ragweed: Why mention only total pollen count and not air pollution levels?. International Forum of Allergy and Rhinology, 2022, 12, 886-888.	2.8	1
11	Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies. Journal of Experimental Pharmacology, 2022, Volume 14, 1-5.	3.2	4
12	The future of inhalation therapy in chronic obstructive pulmonary disease. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100092.	3.6	8
13	Prescribing the right therapy for the treatment of chronic cough: a critical focus on current and investigational options. Expert Opinion on Pharmacotherapy, 2022, , 1-4.	1.8	0
14	Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma. Pulmonary Pharmacology and Therapeutics, 2022, 73-74, 102125.	2.6	6
15	Dual bronchodilation for the treatment of COPD: From bench to bedside. British Journal of Clinical Pharmacology, 2022, 88, 3657-3673.	2.4	10
16	Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile. Journal of Asthma and Allergy, 2022, Volume 15, 565-577.	3.4	6
17	A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. Expert Review of Clinical Pharmacology, 2022, 15, 269-283.	3.1	0
18	Systematic Literature Review of Treatments Used for Refractory or Unexplained Chronic Cough in Adults. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
19	The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. <i>European Respiratory Review</i> , 2022, 31, 210196.	7.1	8
20	Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 917-927.	1.8	4
21	Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis. <i>Cells</i> , 2022, 11, 1797.	4.1	7
22	An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1205-1216.	1.8	4
23	Muscarinic receptor antagonists and airway inflammation: A systematic review on pharmacological models. <i>Heliyon</i> , 2022, 8, e09760.	3.2	2
24	The 5T approach in asthma: Triple Therapy Targeting Treatable Traits. <i>Respiratory Medicine</i> , 2022, 200, 106915.	2.9	11
25	Unmet Needs and the Future of Asthma-Chronic Pulmonary Obstructive Disease Overlap. <i>Immunology and Allergy Clinics of North America</i> , 2022, , .	1.9	3
26	Radiological pitfalls associated with the diagnosis of usual interstitial pneumonia pattern on high-resolution computed tomography and associated findings: experience from a single Italian center. <i>Acta Radiologica</i> , 2021, 62, 619-627.	1.1	2
27	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. <i>Journal of Affective Disorders</i> , 2021, 278, 339-340.	4.1	11
28	Advances in understanding of mechanisms related to increased cardiovascular risk in COPD. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 59-70.	2.5	8
29	Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 561-568.	2.5	27
30	Guidance on nebulization during the current COVID-19 pandemic. <i>Respiratory Medicine</i> , 2021, 176, 106236.	2.9	35
31	Prospects for severe asthma treatment. <i>Current Opinion in Pharmacology</i> , 2021, 56, 52-60.	3.5	17
32	Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa588.	0.9	27
33	Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100010.	3.6	4
34	Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. <i>Drug Safety</i> , 2021, 44, 273-290.	3.2	25
35	Mepolizumab Effectiveness and Allergic Status in Real Life. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 311-318.	2.1	4
36	Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 611-620.	1.8	10

#	ARTICLE	IF	CITATIONS
37	Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Review of Respiratory Medicine, 2021, 15, 143-152.	2.5	29
38	Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease. Respiration, 2021, 100, 291-297.	2.6	7
39	Electrocardiographic modifications and cardiac involvement in COVID-19 patients: results from an Italian cohort. Journal of Cardiovascular Medicine, 2021, 22, 190-196.	1.5	3
40	Drug interaction and chronic obstructive respiratory disorders. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100009.	3.6	9
41	Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. European Respiratory Journal, 2021, 58, 2004233.	6.7	31
42	Happy hypoxemia, or blunted ventilation?. Respiratory Research, 2021, 22, 4.	3.6	9
43	Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma. Clinical Respiratory Journal, 2021, 15, 237-243.	1.6	4
44	Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. Expert Opinion on Drug Delivery, 2021, 18, 891-906.	5.0	7
45	The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review. International Journal of COPD, 2021, Volume 16, 257-279.	2.3	17
46	Comparative studies of dual bronchodilation in COPD. Monaldi Archives for Chest Disease, 2021, 91, .	0.6	3
47	Treatable Mechanisms in Asthma. Molecular Diagnosis and Therapy, 2021, 25, 111-121.	3.8	17
48	Inhaled long-acting muscarinic antagonists in asthma â€” A narrative review. European Journal of Internal Medicine, 2021, 85, 14-22.	2.2	18
49	Can placebo challenge test (inducing a â€œnocebo effectâ€) be a suitable model to assess stress-induced bronchial obstruction? Suggestions from the multidisciplinary Working Groups â€œStress-Asthmaâ€ and â€œAAIITO Regione Campaniaâ€. European Annals of Allergy and Clinical Immunology, 2021, 53, 284.	1.0	0
50	New Avenues for Phosphodiesterase Inhibitors in Asthma. Journal of Experimental Pharmacology, 2021, Volume 13, 291-302.	3.2	17
51	Sex differences in COPD management. Expert Review of Clinical Pharmacology, 2021, 14, 323-332.	3.1	16
52	SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. Vaccines, 2021, 9, 227.	4.4	47
53	Response to letter to the editor. Again on IMPACT: exacerbation after abrupt discontinuation of ICS and pneumonia in fluticasone furoate-containing FDCs. Expert Opinion on Pharmacotherapy, 2021, 22, 943-945.	1.8	0
54	Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. Vaccines, 2021, 9, 341.	4.4	24

#	ARTICLE	IF	CITATIONS
55	Mortality in ETHOS: A Question of "Power". American Journal of Respiratory and Critical Care Medicine, 2021, 203, 926-927.	5.6	3
56	Quasibobar minimalist lung volume reduction surgery. European Journal of Cardio-thoracic Surgery, 2021, 60, 598-606.	1.4	5
57	Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom. Journal of Clinical Medicine, 2021, 10, 1607.	2.4	21
58	Management of COPD patients during COVID: difficulties and experiences. Expert Review of Respiratory Medicine, 2021, 15, 1025-1033.	2.5	4
59	Step-up and step-down approaches in the treatment of asthma. Expert Review of Respiratory Medicine, 2021, 15, 1159-1168.	2.5	9
60	Disputes over the production and dissemination of misinformation in the time of COVID-19. Respiratory Medicine, 2021, 182, 106380.	2.9	4
61	Assessment of self-reported and objective daytime sleepiness in adult-onset myotonic dystrophy type 1. Journal of Clinical Sleep Medicine, 2021, 17, 2383-2391.	2.6	5
62	Atherogenic Dyslipidemia on Admission Is Associated With Poorer Outcome in People With and Without Diabetes Hospitalized for COVID-19. Diabetes Care, 2021, 44, 2149-2157.	8.6	20
63	Current long-acting muscarinic antagonists for the treatment of asthma. Expert Opinion on Pharmacotherapy, 2021, 22, 1-15.	1.8	1
64	Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence. International Journal of Molecular Sciences, 2021, 22, 7132.	4.1	6
65	Sex differences in excessive oral corticosteroid exposure in poor adherent adult asthmatics overusing short-acting β_2 -agonists. Minerva Medica, 2021, , .	0.9	0
66	Face masks during COVID-19 pandemic lockdown and self-reported seasonal allergic rhinitis symptoms. Rhinology, 2021, 59, 0-0.	1.3	5
67	Use of Thiols in the Treatment of COVID-19: Current Evidence. Lung, 2021, 199, 335-343.	3.3	16
68	Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102050.	2.6	7
69	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. Biologics: Targets and Therapy, 2021, Volume 15, 363-374.	3.2	10
70	Which LABA/LAMA should be chosen in COPD patients in real life?. Pulmonary Pharmacology and Therapeutics, 2021, 71, 102076.	2.6	3
71	Incidence of pneumomediastinum in COVID-19: A single-center comparison between 1st and 2nd wave. Respiratory Investigation, 2021, 59, 661-665.	1.8	14
72	Multi-walled carbon nanotubes induce airway hyperresponsiveness in human bronchi by stimulating sensory C-fibers and increasing the release of neuronal acetylcholine. Expert Review of Respiratory Medicine, 2021, 15, 1473-1481.	2.5	5

#	ARTICLE	IF	CITATIONS
73	The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review. <i>Biomedicines</i> , 2021, 9, 1281.	3.2	13
74	Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. <i>Pharmacological Research</i> , 2021, 172, 105801.	7.1	18
75	Controversy surrounding the Sputnik V vaccine. <i>Respiratory Medicine</i> , 2021, 187, 106569.	2.9	28
76	Editorial overview: Respiratory: Pulmonary pharmacologyâ€œThe emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives. <i>Current Opinion in Pharmacology</i> , 2021, 60, 54-58.	3.5	3
77	SMART for the treatment of asthma: A network meta-analysis of real-world evidence. <i>Respiratory Medicine</i> , 2021, 188, 106611.	2.9	9
78	Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 579-581.	2.5	4
79	Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.6	3
80	Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review. <i>Respiratory Medicine</i> , 2021, 189, 106639.	2.9	4
81	Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence?. <i>US Respiratory & Pulmonary Diseases</i> , 2021, 6, 31.	0.2	1
82	Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial. <i>BMC Pulmonary Medicine</i> , 2021, 21, 396.	2.0	0
83	Use of face masks and allergic nasal symptoms: Why not mention pollen count and air pollution data?. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, , 103363.	1.3	0
84	Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis. <i>Acta Radiologica</i> , 2020, 61, 204-218.	1.1	0
85	Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle <i>ex vivo</i> . <i>British Journal of Pharmacology</i> , 2020, 177, 1150-1163.	5.4	47
86	Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , 2020, 6, 47-66.	2.2	63
87	A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 60, 101883.	2.6	7
88	The impact of comorbidities on severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 47-55.	2.6	40
89	Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. <i>Drugs</i> , 2020, 80, 1799-1809.	10.9	21
90	Expression profiles of the SARS-CoV-2 host invasion genes in nasopharyngeal and oropharyngeal swabs of COVID-19 patients. <i>Heliyon</i> , 2020, 6, e05143.	3.2	23

#	ARTICLE	IF	CITATIONS
91	Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis. Respiratory Medicine and Research, 2020, 78, 100791.	0.6	2
92	Use of mucolytics in COPD: A Delphi consensus study. Respiratory Medicine, 2020, 175, 106190.	2.9	4
93	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. Journal of Clinical Medicine, 2020, 9, 2397.	2.4	6
94	Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. Neurological Sciences, 2020, 41, 2671-2674.	1.9	6
95	Pharmacological management of adult patients with acute respiratory distress syndrome. Expert Opinion on Pharmacotherapy, 2020, 21, 2169-2183.	1.8	6
96	Are there pulmonary sequelae in patients recovering from COVID-19?. Respiratory Research, 2020, 21, 286.	3.6	42
97	COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells. Genes, 2020, 11, 1010.	2.4	88
98	Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. Expert Review of Clinical Pharmacology, 2020, 13, 977-990.	3.1	10
99	<p>Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review</p>. Journal of Experimental Pharmacology, 2020, Volume 12, 233-253.	3.2	16
100	Targeting ILâ€5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab. British Journal of Pharmacology, 2020, 177, 4750-4765.	5.4	17
101	Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. Human Genomics, 2020, 14, 29.	2.9	60
102	<p>Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy</p>. Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 261-271.	0.7	6
103	Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. Respiratory Medicine, 2020, 171, 106114.	2.9	23
104	Advances with glucocorticoids in the treatment of asthma: state of the art. Expert Opinion on Pharmacotherapy, 2020, 21, 2305-2316.	1.8	23
105	The latest on the role of LAMAs in asthma. Journal of Allergy and Clinical Immunology, 2020, 146, 1288-1291.	2.9	17
106	<scp>HLA</scp> allele frequencies and susceptibility to <scp>COVID</scp>â€19 in a group of 99 Italian patients. Hla, 2020, 96, 610-614.	0.6	130
107	SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. European Respiratory Journal, 2020, 56, 2000625.	6.7	46
108	Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). Expert Opinion on Investigational Drugs, 2020, 29, 723-738.	4.1	5

#	ARTICLE	IF	CITATIONS
109	Does bronchoscopy help the diagnosis in COVID-19 infection?. European Respiratory Journal, 2020, 56, 2001619.	6.7	27
110	<p><p>Day and Night Control of COPD and Role of Pharmacotherapy: A Review</p></p>. International Journal of COPD, 2020, Volume 15, 1269-1285.	2.3	12
111	What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis. Respiratory Medicine, 2020, 166, 105937.	2.9	6
112	A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2399-2401.	3.8	5
113	Pharmacology and Therapeutics of Bronchodilators Revisited. Pharmacological Reviews, 2020, 72, 218-252.	16.0	104
114	<p>Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study</p>. Risk Management and Healthcare Policy, 2020, Volume 13, 43-53.	2.5	11
115	Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. Expert Review of Respiratory Medicine, 2020, 14, 621-635.	2.5	2
116	Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Delivery, 2020, 17, 635-646.	5.0	39
117	The role of triple therapy in the management of COPD. Expert Review of Clinical Pharmacology, 2020, 13, 865-874.	3.1	7
118	TSLP Inhibitors for Asthma: Current Status and Future Prospects. Drugs, 2020, 80, 449-458.	10.9	51
119	Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. Pulmonary Pharmacology and Therapeutics, 2020, 61, 101899.	2.6	46
120	Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 215-223.	1.6	2
121	Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control?. Monaldi Archives for Chest Disease, 2020, 90, .	0.6	2
122	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain, Behavior, and Immunity, 2020, 88, 11-16.	4.1	159
123	As needed therapies in mild to severe asthma: a systematic review and network meta-analysis. , 2020, , .		2
124	Î±₁-Antitrypsin deficiency and chronic respiratory disorders. European Respiratory Review, 2020, 29, 190073.	7.1	47
125	<p><p>Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease</p></p>. Journal of Experimental Pharmacology, 2020, Volume 12, 559-574.	3.2	12
126	Anxiety depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link. European Annals of Allergy and Clinical Immunology, 2020, 52, 190-192.	1.0	0

#	ARTICLE	IF	CITATIONS
127	Cardiovascular disease in COPD. , 2020, , 47-65.		1
128	PP399 Analysis Of Referral Patterns To Specialized Centers In Idiopathic Pulmonary Fibrosis To Define A New Regional Care Pathway. International Journal of Technology Assessment in Health Care, 2020, 36, 33-33.	0.5	0
129	Ergonomical Assessment of Three-Dimensional Versus Two-Dimensional Thoracoscopic Lobectomy. Seminars in Thoracic and Cardiovascular Surgery, 2020, 32, 1089-1096.	0.6	5
130	Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma. US Respiratory & Pulmonary Diseases, 2020, 5, 18.	0.2	4
131	Sleep and wake impairment in patients with SARS-CoV2 infection. Sleep Medicine, 2020, 73, 177-178.	1.6	0
132	Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy). European Annals of Allergy and Clinical Immunology, 2020, 52, 230.	1.0	1
133	Seasonal monitoring of serum IgE and blood eosinophil variability may lead to a better severe asthma phenotyping and to a correct biologic prescription. Journal of Biological Regulators and Homeostatic Agents, 2020, 34, 315-318.	0.7	3
134	Disease awareness in patients with COPD: measurement and extent. International Journal of COPD, 2019, Volume 14, 1-11.	2.3	9
135	Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice?. International Archives of Allergy and Immunology, 2019, 180, 142-143.	2.1	0
136	Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. Multidisciplinary Respiratory Medicine, 2019, 14, 25.	1.5	10
137	Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101828.	2.6	16
138	CD71 ^{hi} Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1444-1446.	5.6	0
139	Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. Molecular Diagnosis and Therapy, 2019, 23, 603-614.	3.8	15
140	Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1643-1646.	3.8	8
141	Minimalist Thoracoscopic Biopsy of Interstitial Lung Disease. , 2019, , .		0
142	Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101855.	2.6	16
143	Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101841.	2.6	32
144	DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE.. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019065.	1.3	7

#	ARTICLE	IF	CITATIONS
145	Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β_2 -Agonists in COPD: Accumulating Evidence from Network Meta-Analyses. <i>Pulmonary Therapy</i> , 2019, 5, 117-126.	2.2	8
146	Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. <i>Advances in Therapy</i> , 2019, 36, 3291-3298.	2.9	18
147	Ultra-LABAs for the treatment of asthma. <i>Respiratory Medicine</i> , 2019, 156, 47-52.	2.9	15
148	Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2019, 156, 78-84.	2.9	21
149	A potential role of triple therapy for asthma patients. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1079-1085.	2.5	18
150	Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 827-833.	4.1	26
151	Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 215-226.	1.6	16
152	The prognostic role of Genderâ€Ageâ€Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. <i>Clinical Respiratory Journal</i> , 2019, 13, 166-173.	1.6	6
153	Monoclonal antibodies in severe asthma: is it worth it?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 517-520.	3.3	13
154	Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. <i>Respiratory Medicine</i> , 2019, 154, 86-92.	2.9	35
155	Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 452-463.	8.7	42
156	Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. <i>Respiratory Research</i> , 2019, 20, 104.	3.6	45
157	Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up. <i>Respiratory Medicine</i> , 2019, 153, 68-75.	2.9	3
158	Response. <i>Chest</i> , 2019, 155, 1079-1080.	0.8	1
159	Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. <i>Respiratory Medicine</i> , 2019, 153, 3-13.	2.9	35
160	Cardiovascular Disease in Chronic Respiratory Disorders and Beyond. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2178-2180.	2.8	8
161	Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 56, 39-50.	2.6	21
162	Bronchodilators in subjects with asthma-related comorbidities. <i>Respiratory Medicine</i> , 2019, 151, 43-48.	2.9	12

#	ARTICLE	IF	CITATIONS
163	Adding a LAMA to ICS/LABA Therapy. Chest, 2019, 155, 758-770.	0.8	65
164	Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it. Journal of Allergy and Clinical Immunology, 2019, 143, 1657-1658.	2.9	6
165	The future of bronchodilation: looking for new classes of bronchodilators. European Respiratory Review, 2019, 28, 190095.	7.1	24
166	Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661988812.	2.6	12
167	Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis. Interactive Cardiovascular and Thoracic Surgery, 2019, 28, 744-750.	1.1	20
168	Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. World Allergy Organization Journal, 2019, 12, 100081.	3.5	11
169	Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2019, 20, 737-750.	1.8	13
170	Pharmacological treatment and current controversies in COPD. F1000Research, 2019, 8, 1533.	1.6	27
171	Allergy in adolescent population (14-18 years) living in Campania region (Southern Italy). A multicenter study. European Annals of Allergy and Clinical Immunology, 2019, 51, 44.	1.0	3
172	The possible concomitant use of aeroallergen and food panels for skin prick testing might enhance the risk of generalized allergic reactions in children. Turkish Journal of Pediatrics, 2019, 61, 815.	0.6	2
173	Ensifentrine. Dual phosphodiesterase PDE3/4 inhibitor, Treatment of COPD, Treatment of cystic fibrosis. Drugs of the Future, 2019, 44, 845.	0.1	1
174	Systemic pharmacotherapy. , 2019, , 215-222.		0
175	Critical interpretation of pairwise and network meta-analysis of randomized respiratory clinical trials. AboutOpen, 2019, 6, 55-61.	0.2	0
176	Why Are Allergens Not Detected in the Bronchoalveolar Lavage Fluid of Patients Undergoing Fiberoptic Bronchoscopy? Possible Explanations. Journal of Investigational Allergology and Clinical Immunology, 2019, 29, 472-473.	1.3	0
177	Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. Pulmonary Pharmacology and Therapeutics, 2018, 49, 88-94.	2.6	7
178	A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety, 2018, 17, 509-517.	2.4	6
179	Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. Expert Opinion on Drug Safety, 2018, 17, 429-435.	2.4	15
180	Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 50, 28-37.	2.6	13

#	ARTICLE	IF	CITATIONS
181	Is ICSâ€“LAMA an alternative option to treat patients with COPD?. Lancet Respiratory Medicine,the, 2018, 6, 316-317.	10.7	7
182	Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. Expert Review of Respiratory Medicine, 2018, 12, 261-264.	2.5	26
183	Clinical effect of corticosteroids in asthmaâ€“affected horses: A quantitative synthesis. Equine Veterinary Journal, 2018, 50, 594-601.	1.7	11
184	Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy?. Human Vaccines and Immunotherapeutics, 2018, 14, 1438-1441.	3.3	6
185	Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. Current Opinion in Pharmacology, 2018, 40, 34-38.	3.5	20
186	Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 239-245.	3.3	9
187	Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. Pulmonary Pharmacology and Therapeutics, 2018, 49, 20-26.	2.6	2
188	Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. Respiratory Research, 2018, 19, 65.	3.6	30
189	The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opinion on Drug Safety, 2018, 17, 589-596.	2.4	13
190	Impact of doxofylline in COPD: A pairwise meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 51, 1-9.	2.6	17
191	Combining longâ€“acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, 546-554.	1.3	9
192	How does race/ethnicity influence pharmacological response to asthma therapies?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 435-446.	3.3	24
193	An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. Expert Review of Respiratory Medicine, 2018, 12, 43-54.	2.5	14
194	Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2018, 12, 103-112.	2.5	1
195	Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 48, 185-194.	2.6	20
196	Anxiety and asthma in youth. Is a stressâ€“induced increased cholinergic tone the possible link?. Pediatric Pulmonology, 2018, 53, 128-129.	2.0	1
197	Staged unilateral lung volume reduction surgery: from mini-invasive to minimalist treatment strategies. Journal of Thoracic Disease, 2018, 10, S2754-S2762.	1.4	5
198	Occupational exposure to furry animals and asthma. Annals of Allergy, Asthma and Immunology, 2018, 121, 512-513.	1.0	1

#	ARTICLE	IF	CITATIONS
199	Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1101-1111.	3.3	10
200	LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. International Journal of COPD, 2018, Volume 13, 3115-3130.	2.3	32
201	Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert Opinion on Pharmacotherapy, 2018, 19, 2043-2053.	1.8	5
202	Triple therapy <i>versus</i> single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. European Respiratory Journal, 2018, 52, 1801586.	6.7	101
203	Indoor environmental interventions for furry pet allergens: How to decrease the degree of passive transport. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1808-1809.	3.8	0
204	LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life. Respiration, 2018, 96, 370-381.	2.6	2
205	Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity. Lung, 2018, 196, 707-713.	3.3	9
206	Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. European Journal of Pharmacology, 2018, 832, 114-119.	3.5	12
207	Multifaceted activity of N-acetyl-L-cysteine in chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2018, 12, 693-708.	2.5	30
208	Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. BMJ Evidence-Based Medicine, 2018, 23, 183-184.	3.5	1
209	Emerging antibacterial and antiviral drugs for treating respiratory tract infections. Expert Opinion on Emerging Drugs, 2018, 23, 185-199.	2.4	2
210	Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulmonary Medicine, 2018, 18, 70.	2.0	53
211	Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?. Expert Opinion on Investigational Drugs, 2018, 27, 573-581.	4.1	18
212	Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 310-311.	1.6	7
213	N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. Biomedicine and Pharmacotherapy, 2018, 103, 1-8.	5.6	20
214	Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. Clinical and Molecular Allergy, 2018, 16, 3.	1.8	15
215	Associated Pulmonary Hypertension Is an Independent Contributor to Exercise Intolerance in Chronic Fibrosing Interstitial Pneumonias. Respiration, 2018, 96, 543-551.	2.6	7
216	Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection?. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1093-1094.	3.8	0

#	ARTICLE	IF	CITATIONS
217	Impact of doxofylline in COPD: a pair-wise meta-analysis. , 2018, , .		1
218	Dog allergy: can a prevalent or exclusive sensitization to Can f 5 be considered a lucky or negative event in "œreal life"? European Annals of Allergy and Clinical Immunology, 2018, 50, 283.	1.0	6
219	LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. European Respiratory Review, 2017, 26, 160043.	7.1	50
220	Role of muscarinic antagonists in asthma therapy. Expert Review of Respiratory Medicine, 2017, 11, 239-253.	2.5	27
221	Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respiratory Research, 2017, 18, 26.	3.6	60
222	Optimizing drug delivery in COPD: The role of inhaler devices. Respiratory Medicine, 2017, 124, 6-14.	2.9	131
223	Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?. European Respiratory Journal, 2017, 49, 1602345.	6.7	11
224	Pharmacological treatments in asthmaâ€œaffected horses: A pairâ€œwise and network metaâ€œanalysis. Equine Veterinary Journal, 2017, 49, 710-717.	1.7	28
225	Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "œreal life"? Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 535.	3.8	6
226	The Challenges of Precision Medicine in COPD. Molecular Diagnosis and Therapy, 2017, 21, 345-355.	3.8	37
227	Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents?. Expert Opinion on Pharmacotherapy, 2017, 18, 833-835.	1.8	4
228	Indacaterol/Glycopyrronium Combination for COPD. Pulmonary Therapy, 2017, 3, 45-57.	2.2	2
229	An update on the pharmacotherapeutic management of lower respiratory tract infections. Expert Opinion on Pharmacotherapy, 2017, 18, 973-988.	1.8	9
230	Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine. EBioMedicine, 2017, 19, 14-15.	6.1	12
231	Adherence to COPD treatment: Myth and reality. Respiratory Medicine, 2017, 129, 117-123.	2.9	64
232	Bronchodilator therapy for chronic cough. Pulmonary Pharmacology and Therapeutics, 2017, 47, 88-92.	2.6	12
233	Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. Pulmonary Pharmacology and Therapeutics, 2017, 45, 148-158.	2.6	54
234	Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Immunology: in Practice, 2017, 5, 873.	3.8	3

#	ARTICLE	IF	CITATIONS
235	Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. Pulmonary Pharmacology and Therapeutics, 2017, 44, 83-87.	2.6	11
236	Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs, 2017, 77, 721-732.	10.9	29
237	Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. Journal of Comparative Effectiveness Research, 2017, 6, 627-636.	1.4	5
238	Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. European Journal of Pharmacology, 2017, 812, 147-154.	3.5	28
239	Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 526-532.	1.6	17
240	Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 552-563.	1.6	77
241	Anaphylaxis and intimate behaviour. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 350-355.	2.3	11
242	Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. Trends in Pharmacological Sciences, 2017, 38, 940-951.	8.7	46
243	In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV1 than long-acting beta-agonists plus inhaled corticosteroids. Evidence-Based Medicine, 2017, 22, 183-184.	0.6	3
244	Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 641-647.	1.6	9
245	Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. Respiratory Medicine, 2017, 129, 189-198.	2.9	54
246	Tiotropium formulations and safety: a network meta-analysis. Therapeutic Advances in Drug Safety, 2017, 8, 17-30.	2.4	25
247	Multi-Dimensional Assessment in Idiopathic Pulmonary Fibrosis. Chest, 2017, 152, A446.	0.8	0
248	Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals?. Journal of Occupational Health, 2017, 59, 310-311.	2.1	0
249	Acute exacerbations of COPD: risk factors for failure and relapse. International Journal of COPD, 2017, Volume 12, 2687-2693.	2.3	37
250	What Could the Role of Can f 5 Allergen Be in Dog- Sensitized Patients in "Real Life"? Journal of Investigational Allergology and Clinical Immunology, 2017, 27, 397-398.	1.3	5
251	The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. International Journal of COPD, 2017, Volume 12, 3469-3485.	2.3	35
252	Protein tyrosin kinase and KCa++ channel: two faces of the same coin in LABA/LAMA synergy. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
253	Clinical synergism of LABA/LAMA combinations in COPD patients. , 2017, , .		1
254	Benralizumab for the treatment of asthma. <i>Drugs of Today</i> , 2017, 53, 633.	1.1	6
255	Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience. <i>European Annals of Allergy and Clinical Immunology</i> , 2017, 49, 92-96.	1.0	1
256	Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract. <i>New Microbiologica</i> , 2017, 40, 107-112.	0.1	1
257	Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals?. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2016, 26, 403-405.	1.3	1
258	Minimalist video-assisted thoracic surgery biopsy of mediastinal tumors. <i>Journal of Thoracic Disease</i> , 2016, 8, 3704-3710.	1.4	8
259	The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. <i>BioMed Research International</i> , 2016, 2016, 1-7.	1.9	8
260	Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. <i>Respiratory Research</i> , 2016, 17, 70.	3.6	71
261	Airflow obstruction: is it asthma or is it COPD?. <i>International Journal of COPD</i> , 2016, Volume 11, 3007-3013.	2.3	52
262	The effect of N -acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. <i>Respiratory Medicine</i> , 2016, 117, 190-197.	2.9	136
263	LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. <i>Evidence-Based Medicine</i> , 2016, 21, 222-222.	0.6	9
264	Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens. <i>Upsala Journal of Medical Sciences</i> , 2016, 121, 196-197.	0.9	1
265	Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life?. <i>Allergologia Et Immunopathologia</i> , 2016, 44, 387-388.	1.7	7
266	An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. <i>International Journal of Mycobacteriology</i> , 2016, 5, 244-247.	0.6	15
267	Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. <i>Drug Safety</i> , 2016, 39, 501-508.	3.2	28
268	A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. <i>Chest</i> , 2016, 149, 1181-1196.	0.8	206
269	Chronic cat allergen exposure and low sensitization: Possible limitations in patient selection?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1621-1622.	2.9	5
270	The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 733-744.	5.0	39

#	ARTICLE	IF	CITATIONS
271	Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 40, 95-103.	2.6	112
272	Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 1.7	1.7	6
273	Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , 2016, 76, 1257-1270.	10.9	36
274	Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 791-793.	3.8	7
275	The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators. <i>Pharmacological Research</i> , 2016, 111, 659-667.	7.1	10
276	Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 804-814.	2.9	54
277	Brain natriuretic peptide: Much more than a biomarker. <i>International Journal of Cardiology</i> , 2016, 221, 1031-1038.	1.7	51
278	Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 39, 48-53.	2.6	7
279	Gastroesophageal reflux and <sc>COPD</sc> exacerbations: Is cholinergicâ€mediated oesophagoâ€bronchial reflex a possible link?. <i>Respirology</i> , 2016, 21, 1496-1497.	2.3	1
280	Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1133-1146.	2.4	47
281	Do we really need asthmaâ€chronic obstructive pulmonary disease overlap syndrome?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 977-983.	2.9	52
282	Dog allergen immunotherapy and allergy to furry animals. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 590.	1.0	2
283	Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. <i>Respiratory Medicine</i> , 2016, 117, 150-153.	2.9	26
284	Interaction between corticosteroids and muscarinic antagonists in human airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 36, 1-9.	2.6	47
285	Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 977-988.	1.8	9
286	How many systemic reactions to skin prick tests could be preventable in defined conditions?. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 174.	1.0	4
287	Serum- and Glucocorticoid-Inducible Kinase 1 Delay the Onset of Endothelial Senescence by Directly Interacting with Human Telomerase Reverse Transcriptase. <i>Rejuvenation Research</i> , 2016, 19, 79-89.	1.8	6
288	Occupational allergy to horse allergens: More than exposure to horses!. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2016, 29, 721-723.	1.3	0

#	ARTICLE	IF	CITATIONS
289	Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies. European Annals of Allergy and Clinical Immunology, 2016, 48, 61-4.	1.0	9
290	Chronic obstructive pulmonary disease and diabetes. COPD Research and Practice, 2015, 1, .	0.7	27
291	Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. COPD Research and Practice, 2015, 1, .	0.7	33
292	Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulmonary Pharmacology and Therapeutics, 2015, 32, 15-23.	2.6	46
293	Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma. Pulmonary Pharmacology and Therapeutics, 2015, 33, 1-10.	2.6	14
294	Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opinion on Drug Safety, 2015, 14, 533-541.	2.4	36
295	Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology, 2015, 8, 35-41.	3.1	8
296	Indacaterol for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2015, 16, 107-115.	1.8	6
297	Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics, 2015, 31, 15-27.	2.6	57
298	Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 175-181.	1.6	73
299	Influence of ethnicity on response to asthma drugs. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1089-1097.	3.3	14
300	Cardiovascular disease in patients with COPD. Lancet Respiratory Medicine,the, 2015, 3, 593-595.	10.7	22
301	Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respiratory Medicine, 2015, 109, 1019-1025.	2.9	21
302	QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2015, 16, 1079-1090.	1.8	14
303	Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. Drugs, 2015, 75, 1575-1585.	10.9	30
304	Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. Life Sciences, 2015, 131, 44-50.	4.3	20
305	Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology, 2015, 8, 529-539.	3.1	10
306	Novel glucocorticoid receptor agonists in the treatment of asthma. Expert Opinion on Investigational Drugs, 2015, 24, 1473-1482.	4.1	17

#	ARTICLE	IF	CITATIONS
307	Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. European Respiratory Review, 2015, 24, 451-461.	7.1	140
308	Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. Respiratory Medicine, 2015, 109, 1305-1311.	2.9	54
309	Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. European Journal of Pharmacology, 2015, 761, 383-390.	3.5	31
310	Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. Drugs of Today, 2015, 51, 469.	1.1	6
311	Urgent awake thoracoscopic treatment of retained haemothorax associated with respiratory failure. Annals of Translational Medicine, 2015, 3, 112.	1.7	0
312	The complex care of severe emphysema: role of awake lung volume reduction surgery. Annals of Translational Medicine, 2015, 3, 108.	1.7	8
313	The clinical use of regenerative therapy in COPD. International Journal of COPD, 2014, 9, 1389.	2.3	5
314	Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. European Journal of Pharmacology, 2014, 745, 135-143.	3.5	80
315	Brain Natriuretic Peptide Protects against Hyperresponsiveness of Human Asthmatic Airway Smooth Muscle via an Epithelial Cell-Dependent Mechanism. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 493-501.	2.9	20
316	Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. Expert Opinion on Drug Discovery, 2014, 9, 595-607.	5.0	8
317	Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. Respiratory Medicine, 2014, 108, 307-313.	2.9	5
318	Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?. Drugs, 2014, 74, 1983-1992.	10.9	26
319	Umeclidinium for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2014, 8, 665-671.	2.5	16
320	Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2014, 15, 961-977.	1.8	26
321	Diabetes mellitus among outpatients with COPD attending a university hospital. Acta Diabetologica, 2014, 51, 933-940.	2.5	40
322	Defining Phenotypes in COPD: An Aid to Personalized Healthcare. Molecular Diagnosis and Therapy, 2014, 18, 381-388.	3.8	46
323	New Treatments for COPD in the Elderly. Current Pharmaceutical Design, 2014, 20, 5968-5982.	1.9	9
324	Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 414-423.	2.5	80

#	ARTICLE	IF	CITATIONS
325	Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Respiratory Medicine, 2013, 107, 848-853.	2.9	16
326	A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. Respiratory Medicine, 2013, 107, 2014-2021.	2.9	12
327	The effect of indacaterol during an acute exacerbation of COPD. Pulmonary Pharmacology and Therapeutics, 2013, 26, 630-634.	2.6	21
328	The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle. Pulmonary Pharmacology and Therapeutics, 2013, 26, 325-331.	2.6	35
329	Awake Thoracoscopic Biopsy of Interstitial Lung Disease. Annals of Thoracic Surgery, 2013, 95, 445-452.	1.3	89
330	Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. Pulmonary Pharmacology and Therapeutics, 2013, 26, 156-157.	2.6	7
331	Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit. Respiratory Medicine, 2013, 107, 1417-1422.	2.9	22
332	Î²₂-Agonist Therapy in Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 690-696.	5.6	221
333	Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2013, 14, 775-781.	1.8	32
334	Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respiratory Medicine, 2013, 107, 107-111.	2.9	10
335	Comorbidities of asthma. Current Opinion in Pulmonary Medicine, 2013, 19, 36-41.	2.6	53
336	Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2013, 14, 2489-2499.	1.8	28
337	Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. European Respiratory Journal, 2012, 40, 101-109.	6.7	179
338	Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. Respiratory Medicine, 2012, 106, 249-256.	2.9	89
339	An update on bronchodilators in Phase I and II clinical trials. Expert Opinion on Investigational Drugs, 2012, 21, 1489-1501.	4.1	32
340	Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. Current Opinion in Pharmacology, 2012, 12, 300-308.	3.5	20
341	High Glucose Enhances Responsiveness of Human Airways Smooth Muscle via the Rho/ROCK Pathway. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 509-516.	2.9	66
342	Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 47-54.e1.	0.8	112

#	ARTICLE	IF	CITATIONS
343	Comparative effectiveness of drugs for chronic obstructive pulmonary disease. <i>Drugs of Today</i> , 2012, 48, 785.	1.1	28
344	Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011, 24, 221-226.	2.6	40
345	Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2011, 20, 291-298.	2.3	36
346	Asthma and comorbid medical illness. <i>European Respiratory Journal</i> , 2011, 38, 42-49.	6.7	98
347	Combined Pulmonary Fibrosis and Emphysema: 3D Time-resolved MR Angiographic Evaluation of Pulmonary Arterial Mean Transit Time and Time to Peak Enhancement. <i>Radiology</i> , 2010, 254, 601-608.	7.3	40
348	Metabolic syndrome and risk of pulmonary involvement. <i>Respiratory Medicine</i> , 2010, 104, 47-51.	2.9	18
349	Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: <i>of Churgâ€ Strauss syndrome?</i> . <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1389-1390.	5.7	13
350	Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 478-482.	2.6	27
351	A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 522-525.	2.6	11
352	Biomarkers of lung damage associated with tobacco smoke in induced sputum. <i>Respiratory Medicine</i> , 2009, 103, 1592-1613.	2.9	41
353	Serum CA 15-3 is increased in pulmonary fibrosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2009, 26, 54-63.	0.2	21
354	Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view. <i>Respiratory Medicine</i> , 2008, 102, 321-327.	2.9	30
355	HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. <i>Respiratory Medicine</i> , 2008, 102, 1753-1761.	2.9	54
356	Review: New perspectives in the treatment of idiopathic pulmonary fibrosis. <i>Therapeutic Advances in Respiratory Disease</i> , 2008, 2, 75-93.	2.6	25
357	Treating systemic effects of COPD. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 544-550.	8.7	29
358	Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 129, 73-79.	0.8	15
359	Identification of HLA-DRPhe ²⁴⁷ as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlu ²⁶⁹ . <i>Respiratory Research</i> , 2005, 6, 94.	3.6	26
360	Completion lobectomy after bilateral lung volume reduction for emphysema: salvage option or fancy?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004, 127, 1212-1214.	0.8	1

#	ARTICLE	IF	CITATIONS
361	Feasibility and Results of Awake Thoracoscopic Resection of Solitary Pulmonary Nodules. Annals of Thoracic Surgery, 2004, 78, 1761-1768.	1.3	244
362	Effect of Lung Volume Reduction Surgery for Severe Emphysema on Right Ventricular Function. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 489-494.	5.6	60
363	HLA-DP-unrestricted TNF- α release in beryllium-stimulated peripheral blood mononuclear cells. European Respiratory Journal, 2002, 20, 1174-1178.	6.7	28
364	Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. glutamate at position 298. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 2832-2835.	7.1	497
365	Thoracoscopic Reduction Pneumoplasty for Severe Emphysema: Do Pleural Adhesions Affect Outcome?. Thoracic and Cardiovascular Surgeon, 1999, 47, 288-292.	1.0	11
366	Endothelial Nitric Oxide Synthase as a Potential Susceptibility Gene in the Pathogenesis of Emphysema in α_1 -Antitrypsin Deficiency. American Journal of Respiratory Cell and Molecular Biology, 1999, 20, 441-447.	2.9	68
367	Unilateral thoracoscopic reduction pneumoplasty for asymmetric emphysema ¹ . European Journal of Cardio-thoracic Surgery, 1998, 14, 33-39.	1.4	11
368	Immunogenesis of Lung Granulomatosis: New Acquisitions. International Journal of Immunopathology and Pharmacology, 1996, 9, 77-77.	2.1	0